Since 1995, CellCept has provided you and your patients with transplant support across its approved indications*1,2

CellCept® (mycophenolate mofetil) is indicated for the prophylaxis of organ rejection in patients receiving allogeneic kidney, heart, or liver transplants. CellCept is the only branded antiproliferative agent that is approved for the prophylaxis of heart and liver transplant rejection.1

  • Indicated for kidney, heart, or liver transplant patients1
  • Available in a variety of formulations to help meet your adult and pediatric patients' needs1
    • Capsule, tablet, oral suspension, and intravenous formulations1
    • Oral suspension for use in your pediatric kidney transplant patients1